• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Vector Group Ltd.

    10/7/24 8:43:24 PM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $VGR alert in real time by email
    SC 13D/A 1 d865011dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    VECTOR GROUP LTD.

    (Name of Issuer)

    Common Stock, $0.10 par value

    (Title of Class of Securities)

    92240M108

    (CUSIP Number)

    Howard M. Lorber

    c/o Vector Group Ltd.

    4400 Biscayne Boulevard, 10th Floor

    Miami, FL 33137

    (305) 579-8000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    October 5, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


       CUSIP No. 92240M108   Page 2

     

     1   

     NAME OF REPORTING PERSON

     

     Howard M. Lorber

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (See Instructions)

     

     OO

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     —

        8  

     SHARED VOTING POWER

     

     —

        9  

     SOLE DISPOSITIVE POWER

     

     —

       10  

     SHARED DISPOSITIVE POWER

     

     —

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     —

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     —

    14  

     TYPE OF REPORTING PERSON (See Instructions)

     

     IN

     


       CUSIP No. 92240M108   Page 3

     

    PRELIMINARY STATEMENT

    This Amendment No. 2 to Schedule 13D amends and supplements the Schedule 13D filed by the Reporting Person with the Securities and Exchange Commission (the “Commission”) on February 16, 2024, as amended by Amendment No. 1 to Schedule 13D filed by the Reporting Person with the Commission on August 22, 2024 (as amended, the “Schedule 13D”), relating to the common stock, par value $0.10 per share (the “Common Stock”), of Vector Group Ltd., a Delaware corporation (the “Company”). Unless otherwise defined herein, all capitalized terms used herein shall have the meanings ascribed to them in the Schedule 13D.

    Item 4. Purpose of Transaction.

    Item 4 of the Schedule 13D is hereby amended and supplemented by inserting the following at the end of such Item:

    Tender of Common Stock and Related Transactions

    Pursuant to the Merger Agreement, and on the terms and subject to the conditions thereof, on September 4, 2024, Merger Sub commenced the Offer.

    The Offer expired at one minute after 11:59 p.m., New York City time, on October 4, 2024, and was not extended (the “Expiration Time”). Equiniti Trust Company, LLC, in its capacity as depository for the Offer, advised the Company that approximately 108,097,425 shares of Common Stock were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 68.67% of the then outstanding Common Stock. Accordingly, the Minimum Condition (as defined in the Merger Agreement) has been satisfied. After the Expiration Time, Merger Sub accepted for payment all shares of Common Stock that were validly tendered and not properly withdrawn pursuant to the Offer, including the 4,643,237 shares of Common Stock tendered by the Reporting Person, and payment for such shares of Common Stock at the Offer Price of $15.00 per share of Common Stock has been or will be made promptly in accordance with the terms of the Offer.

    Following the completion of the Offer, on October 7, 2024, Merger Sub merged with and into the Company pursuant to the Merger, with the separate corporate existence of Merger Sub ceasing and the Company surviving the Merger under the name “Vector Group Ltd.” as a wholly owned subsidiary of Parent, pursuant to the Merger Agreement.

    At the Effective Time, by virtue of the Merger and without any action on the part of the holders of Common Stock, each share of Common Stock that was outstanding immediately prior to the Effective Time, other than shares (i) owned by Parent, Merger Sub or the Company (or held in the Company’s treasury), or by any wholly owned subsidiary of Parent, Merger Sub or the Company, in each case, immediately prior to the Effective Time, (ii) held by stockholders of the Company who were entitled to demand and have properly and validly demanded their statutory rights of appraisal under the laws of the State of Delaware or (iii) irrevocably accepted for payment pursuant to the Offer, was canceled and extinguished and automatically converted into the right to receive the Merger Consideration (as defined in the Merger Agreement), without interest thereon and less any applicable withholding taxes. In addition, at the Effective Time:

     

      •  

    Each Company stock option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, was automatically canceled and converted into the right to receive: (i) with respect to each Company stock option with a per share exercise price that was less than the Merger Consideration (an “In-the-Money Option”), an amount in cash, without interest, equal to the product of (a) the aggregate number of Company Shares underlying such In-the-Money Option immediately prior to the Effective Time and (b) the excess, if any, of (x) the Merger Consideration over (y) the per share exercise price of such In-the-Money Option; and (ii) with respect to each Company stock option with a per share exercise price that was greater than or equal to the Merger Consideration (an “Out-of-the-Money Option”), each such Out-of-the-Money Option was canceled for no consideration. Immediately prior to the Effective Time, the Reporting Person held 262,500 In-the-Money Options and 1,187,976 Out-of-the-Money Options, which were cancelled and converted as described above, respectively.

     

      •  

    With certain exceptions, each award of shares of Common Stock that were subject to a transfer restriction, repurchase option or obligation, risk of forfeiture or other condition, excluding any Company Performance-Based Restricted Share Awards (as defined below) (“Company Time-Based Restricted Share Award”) that was outstanding immediately prior to the Effective Time was automatically canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the aggregate number of shares of Common Stock subject to such Company Time-Based Restricted Share Award immediately prior to the Effective Time and (ii) the Merger Consideration (together with any accrued and unpaid dividends corresponding to the shares of Common Stock subject to such Company Time-Based Restricted Share Award immediately prior to the Effective Time to the extent provided under the applicable award agreement). Immediately prior to the Effective Time, the Reporting Person held 849,500 Company Time-Based Restricted Share Awards, which were cancelled and converted as described above.


       CUSIP No. 92240M108   Page 4

     

      •  

    Each award of shares of Common Stock that were subject to a performance-based transfer restriction, performance-based repurchase option or obligation, performance-based risk of forfeiture or other performance-based conditions, excluding any Company Time-Based Restricted Share Awards (a “Company Performance-Based Restricted Share Award”) that was outstanding immediately prior to the Effective Time was automatically canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the aggregate number of shares of Common Stock subject to such Company Performance-Based Restricted Share Award immediately prior to the Effective Time (based on the full number of shares of Common Stock subject to such Company Performance-Based Restricted Share Award) and (ii) the Merger Consideration (together with any accrued and unpaid dividends corresponding to the shares of Common Stock subject to such Company Performance-Based Restricted Share Award immediately prior to the Effective Time to the extent provided under the applicable award agreement). Immediately prior to the Effective Time, the Reporting Person held 1,205,000 Company Performance-Based Restricted Share Awards, which were cancelled and converted as described above.

    Accordingly, as of the Effective Time, the Reporting Person ceased to beneficially own any securities of the Company and resigned as a director and officer of the Company.

    Item 5. Interest in Securities of the Issuer.

    Item 5 of the Schedule 13D is hereby amended and restated as follows:

     

    (a)-(b)    As a result of the Offer and Merger, as described in Item 4, the Reporting Person no longer beneficially owns any securities of the Company nor has sole or shared power to vote, direct the vote, dispose or direct the disposition with respect to any securities of the Company, and the filing of this Amendment No. 2 represents the final amendment to the Schedule 13D and constitutes an “exit” filing for the Reporting Person.
    (c)    Except as described in Item 4, the Reporting Person has not entered into or effected any transactions in the securities of the Company during the past 60 days.
    (d)    Not applicable.
    (e)    As of October 5, 2024, the Reporting Person ceased to beneficially own more than 5% of the outstanding Common Stock of the Company.

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    Item 6 of the Schedule 13D is hereby amended and restated as follows:

    The information set forth or incorporated by reference in Item 4 of this Schedule 13D is hereby incorporated by reference in this Item 6.


       CUSIP No. 92240M108   Page 5

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: October 7, 2024

     

    By:  

    /s/ J. Bryant Kirkland III, Attorney-In-Fact

      J. Bryant Kirkland III, Attorney-In-Fact
    Get the next $VGR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VGR

    DatePrice TargetRatingAnalyst
    3/31/2022$12.00 → $16.00Equal Weight → Overweight
    Barclays
    11/15/2021$13.00 → $17.00Underweight → Equal Weight
    Barclays
    11/9/2021$18.00Perform → Outperform
    Oppenheimer
    9/13/2021$15.00 → $13.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $VGR
    SEC Filings

    See more
    • SEC Form 15-12G filed by Vector Group Ltd.

      15-12G - VECTOR GROUP LTD (0000059440) (Filer)

      10/17/24 8:00:07 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by Vector Group Ltd.

      EFFECT - VECTOR GROUP LTD (0000059440) (Filer)

      10/8/24 12:15:04 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by Vector Group Ltd.

      EFFECT - VECTOR GROUP LTD (0000059440) (Filer)

      10/8/24 12:15:08 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care

    $VGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Watkins Barry returned $225,000 worth of shares to the company (15,000 units at $15.00), closing all direct ownership in the company (SEC Form 4)

      4 - VECTOR GROUP LTD (0000059440) (Issuer)

      10/7/24 9:41:06 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Officer Bell Marc N was granted 164,500 shares and returned $5,100,000 worth of shares to the company (340,000 units at $15.00), closing all direct ownership in the company (SEC Form 4)

      4 - VECTOR GROUP LTD (0000059440) (Issuer)

      10/7/24 9:14:02 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Sharpe Jean E returned $225,000 worth of shares to the company (15,000 units at $15.00), closing all direct ownership in the company (SEC Form 4)

      4 - VECTOR GROUP LTD (0000059440) (Issuer)

      10/7/24 9:08:43 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care

    $VGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vector Grp upgraded by Barclays with a new price target

      Barclays upgraded Vector Grp from Equal Weight to Overweight and set a new price target of $16.00 from $12.00 previously

      3/31/22 7:41:06 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vector Grp upgraded by Barclays with a new price target

      Barclays upgraded Vector Grp from Underweight to Equal Weight and set a new price target of $17.00 from $13.00 previously

      11/15/21 8:00:05 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vector Group upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Vector Group from Perform to Outperform and set a new price target of $18.00

      11/9/21 6:13:20 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care

    $VGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hims & Hers Health Set to Join S&P SmallCap 600

      NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE:HIMS) will replace Vector Group Ltd (NYSE:VGR) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 9. JT Group is acquiring Vector Group in a deal expected to close soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector October 9, 2024 S&P SmallCap 600 Addition Hims & Hers Health HIMS Health Care S&P SmallCap 600 Deletion Vector Group VGR Consumer Staples For more information about S&P Dow Jones Indices, please visit www.spdji.com

      10/4/24 6:05:00 PM ET
      $HIMS
      $SPGI
      $VGR
      Medical/Nursing Services
      Health Care
      Finance: Consumer Services
      Finance
    • Vector Group Announces Agreement to be Acquired by JT Group

      Delivers significant value for stockholders while positioning Vector Group for long-term success Vector Group Ltd. (NYSE:VGR) today announced that it has entered into a definitive agreement to be acquired by JT Group, a global company headquartered in Tokyo, Japan, operating in tobacco, pharmaceuticals and processed food. JT Group's global tobacco business, headquartered in Geneva, Switzerland, manufactures and sells some of the world's best-known brands in over 130 markets worldwide – including Winston and Camel (outside the U.S.), as well as MEVIUS and LD. Under the terms of the agreement, JT Group will offer to acquire all outstanding shares of Vector Group common stock for $15.00 pe

      8/21/24 6:00:00 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vector Group Declares Quarterly Cash Dividend

      Vector Group Ltd. (NYSE:VGR) today announced that its Board of Directors has declared a regular quarterly cash dividend on its common stock of $0.20 per share. The quarterly cash dividend will be payable on September 12, 2024, to holders of record as of August 30, 2024. Vector Group is a holding company for Liggett Group LLC, Vector Tobacco LLC and New Valley LLC. Additional information concerning the company is available on the Company's website, www.VectorGroupLtd.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240819252290/en/

      8/20/24 3:08:00 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care

    $VGR
    Leadership Updates

    Live Leadership Updates

    See more
    • Hims & Hers Health Set to Join S&P SmallCap 600

      NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE:HIMS) will replace Vector Group Ltd (NYSE:VGR) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 9. JT Group is acquiring Vector Group in a deal expected to close soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector October 9, 2024 S&P SmallCap 600 Addition Hims & Hers Health HIMS Health Care S&P SmallCap 600 Deletion Vector Group VGR Consumer Staples For more information about S&P Dow Jones Indices, please visit www.spdji.com

      10/4/24 6:05:00 PM ET
      $HIMS
      $SPGI
      $VGR
      Medical/Nursing Services
      Health Care
      Finance: Consumer Services
      Finance
    • Douglas Elliman Appoints Richard Ferrari as President and CEO of Brokerage for New York City and the Northeast Region

      Yuval Greenblatt and Alfred Renna Promoted to Senior Managing Director of Operations and Senior Managing Director of Sales, Respectively, for Flagship 575 Madison Avenue Office Douglas Elliman, one of the largest residential real estate brokerages in the United States, announced today that real estate veteran Richard Ferrari has joined the firm as President and CEO of Brokerage for New York City and the Northeast Region. In this role, Ferrari, a highly regarded industry expert, will oversee the firm's New York City resale markets, including Manhattan, Brooklyn, Riverdale and Long Island City in Queens. He will also assume responsibility for Elliman's New Jersey, Westchester, Connecticut a

      7/21/21 8:30:00 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vector Group Appoints Technology Veteran Wilson L. White to its Board of Directors

      Expands Board to 10 Directors with Addition of Silicon Valley Executive Vector Group Ltd. (NYSE:VGR) (the "Company") today announced that it has appointed technology industry veteran, Wilson L. White, to its Board of Directors, effective immediately. Mr. White currently serves as Senior Director of Government Affairs and Public Policy at Google. With Mr. White's appointment, Vector Group's Board expands to 10 directors. "With many years of experience in the technology industry, including government relations and legal expertise, Wilson brings to the Board a unique skillset that will further strengthen Vector Group's commitment to staying at the forefront of our business' rapidly-evolving

      6/22/21 8:00:00 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care

    $VGR
    Financials

    Live finance-specific insights

    See more
    • Vector Group Declares Quarterly Cash Dividend

      Vector Group Ltd. (NYSE:VGR) today announced that its Board of Directors has declared a regular quarterly cash dividend on its common stock of $0.20 per share. The quarterly cash dividend will be payable on September 12, 2024, to holders of record as of August 30, 2024. Vector Group is a holding company for Liggett Group LLC, Vector Tobacco LLC and New Valley LLC. Additional information concerning the company is available on the Company's website, www.VectorGroupLtd.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240819252290/en/

      8/20/24 3:08:00 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vector Group Reports Second Quarter 2024 Financial Results

      Montego maintains position as largest discount brand in the U.S. Second Quarter 2024 Highlights: Consolidated revenues of $371.9 million, up 1.7% or $6.3 million compared to the prior year period. Tobacco segment wholesale market share increased to 5.7% from 5.4% in the prior year period and retail market share remained at 5.8%, unchanged from the prior year period. Montego wholesale and retail market share both increased to 4.1% from 3.4% and 3.5%, respectively, in the prior year period. Operating income of $97.8 million, up 36.5% or $26.1 million compared to the prior year period. Tobacco segment operating income of $102.9 million, up 37.0% or $27.8 million compared to t

      7/31/24 4:45:00 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vector Group to Host Second Quarter 2024 Results Conference Call

      Vector Group Ltd. (NYSE:VGR) will conduct a conference call and webcast to discuss its second quarter 2024 results on Thursday, August 1, 2024 at 8:00 a.m. (ET). Investors may access the call via live webcast at https://www.webcaster4.com/Webcast/Page/2271/50954. Please join the webcast at least 10 minutes prior to start time. A replay of the call will be available shortly after the call ends on August 1, 2024 through August 15, 2024 at https://www.webcaster4.com/Webcast/Page/2271/50954. Vector Group is a holding company for Liggett Group LLC, Vector Tobacco LLC and New Valley LLC. Additional information concerning the company is available on the Company's website, www.VectorGroupLtd.

      7/25/24 8:00:00 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care

    $VGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Vector Group Ltd.

      SC 13D/A - VECTOR GROUP LTD (0000059440) (Subject)

      10/15/24 4:00:16 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Vector Group Ltd.

      SC 13D/A - VECTOR GROUP LTD (0000059440) (Subject)

      10/7/24 8:43:24 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Vector Group Ltd.

      SC 13D/A - VECTOR GROUP LTD (0000059440) (Subject)

      10/1/24 4:27:47 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care